日前都有哪些乳腺癌疫苗？什么时候上市呢？
<div style="color: black; text-align: left; margin-bottom: 10px;"><span style="color: black;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在中国，乳腺癌的发病率在过去十几年<span style="color: black;">显现</span>了<span style="color: black;">显著</span>的快速<span style="color: black;">提升</span>，晚孕、<span style="color: black;">肥壮</span>、抽烟、喝酒、老龄化等等<span style="color: black;">原因</span>都在推动着中国乳腺癌人群的剧增。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2020年预测共新增乳腺癌226万，乳腺癌<span style="color: black;">已然</span>超越肺癌<span style="color: black;">作为</span>了<span style="color: black;">全世界</span><span style="color: black;">第1</span>大癌。每每看到这些数据，都会让科普君吃惊于乳腺癌的普及率，常常期待于哪天乳腺癌<span style="color: black;">亦</span>能和宫颈癌<span style="color: black;">同样</span><span style="color: black;">持有</span>疫苗，让乳腺癌形成之前就能被扼杀在摇篮中！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">而近期<span style="color: black;">海量</span>的<span style="color: black;"><a style="color: black;">乳腺癌疫苗</a></span><span style="color: black;">关联</span>临床<span style="color: black;">实验</span>的开展，给乳腺癌<span style="color: black;">病人</span>和健康女性都带来了<span style="color: black;">期盼</span>！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">三阴性乳腺癌疫苗——预防治疗两手抓</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NO.1 <span style="color: black;"><a style="color: black;">α-乳白蛋白疫苗</a></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">众所皆知，三阴性乳腺癌虽激素受体、HER2表达皆为阴性，但大<span style="color: black;">都数</span>三阴性乳腺癌中存在着一种乳腺特异性分泌乳蛋白——α-乳白蛋白。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">这种乳蛋白有什么特殊之处呢？</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">原来，α-乳白蛋白<span style="color: black;">仅在</span>健康女性身体中仅在妊娠晚期或是哺乳期时在乳房中表达，泌乳结束之后就悄悄离开，直到<span style="color: black;">显现</span>乳腺癌时会再次<span style="color: black;">显现</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">那样</span>注射这种疫苗<span style="color: black;">怎样</span>达到预防三阴性乳腺癌的效果呢？</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">注射这种疫苗之后，<span style="color: black;">能够</span>激活免疫系统。一旦身体<span style="color: black;">显现</span>表达α-乳白蛋白的癌细胞，就能马上被免疫细胞“揪住”，在其还未发展形<span style="color: black;">作为</span>癌症之前将其消灭，以此达到预防的目的。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在10月26日，美国克利夫兰医学中心宣布针对该种疫苗的1期临床<span style="color: black;">实验</span>正式<span style="color: black;">起步</span>，旨在确定确定<span style="color: black;">初期</span>三阴性乳腺癌<span style="color: black;">病人</span>对疫苗的最大耐受剂量，并表征和优化机体的免疫反应。这项<span style="color: black;">实验</span>将纳入18-24名<span style="color: black;">初期</span>三阴性乳腺癌<span style="color: black;">病人</span>，<span style="color: black;">需求</span><span style="color: black;">病人</span>在过去3年完<span style="color: black;">成为了</span>治疗，当前是<span style="color: black;">没</span>癌状态，<span style="color: black;">然则</span>复发<span style="color: black;">危害</span>很高。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NO.2 NeuVax疫苗 </p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NeuVax疫苗是一种基于肽的<span style="color: black;"><a style="color: black;">癌症免疫疗法</a></span>，NeuVax是<span style="color: black;">源自</span>于HER2蛋白的一种免疫原性肽。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NeuVax与免疫佐剂粒细胞-巨噬细胞集落刺激因子<span style="color: black;">一块</span>出战时，能够<span style="color: black;">诱发</span>人体强大的抗HER2免疫应答。<span style="color: black;">不仅</span><span style="color: black;">能够</span>改善<span style="color: black;"><a style="color: black;">HER2阳性乳腺癌</a></span><span style="color: black;">病人</span>的总<span style="color: black;">存活</span>率，<span style="color: black;">况且</span>耐受性良好，不良反应轻微。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">FDA<span style="color: black;">已然</span>为NeuVax用于接受标准护理治疗的HER2表达为低至中等水平<span style="color: black;"><a style="color: black;"><span style="color: black;">初期</span>乳腺癌</a></span>（<span style="color: black;">包含</span>三阴性乳腺癌）<span style="color: black;">病人</span>开通了快速通道。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">日前</span>，NeuVax正在进行III期<span style="color: black;">科研</span>，<span style="color: black;">科研</span>NeuVax疫苗联合<span style="color: black;"><a style="color: black;">曲妥珠单抗</a></span>、GM-CSF单药疗法<span style="color: black;">做为</span>维持疗法，用于三阴性乳腺癌<span style="color: black;">病人</span>标准护理治疗后的辅助治疗。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NO.3 Adagloxad Simolenin疫苗</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Adagloxad Simolenin疫苗<span style="color: black;">便是</span>一种以Globo-H为<span style="color: black;">功效</span>靶点的<span style="color: black;"><a style="color: black;">主动免疫抗癌疗法</a></span>，由Globo-H与载体蛋白<span style="color: black;"><a style="color: black;">KLH</a></span><span style="color: black;">构成</span>。Adagloxad simolenin与皂苷佐剂<span style="color: black;"><a style="color: black;">OBI-821</a></span><span style="color: black;">一起</span>出击时，<span style="color: black;">能够</span>诱导身体产生免疫反应来对抗乳腺癌。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2021年7月7日，Globo-H疫苗已开启国际多中心3期GLORIA<span style="color: black;">科研</span>，是针对三阴性乳腺癌的随机、开放性<span style="color: black;">科研</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">HER2<span style="color: black;"><a style="color: black;">阳性乳腺癌疫苗</a></span>——降低复发转移率</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NO.1 GP2、AE37</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">GP2和AE37都是一种<span style="color: black;"><a style="color: black;">多肽肿瘤疫苗</a></span>，它们都是HER2/neu衍生的<span style="color: black;"><a style="color: black;">短肽疫苗</a></span>。HER2/neu 是一种细胞表面受体蛋白，<span style="color: black;">一般</span>表达于<span style="color: black;"><a style="color: black;">HER2 阳性乳腺癌</a></span>及其他<span style="color: black;">各样</span><span style="color: black;">平常</span>的恶性肿瘤中。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2020年4月施普林格自然旗下《Breast Cancer Res Treat》杂志<span style="color: black;">发布</span>了一项关于<span style="color: black;"><a style="color: black;">GP2和AE37</a></span>疫苗的<span style="color: black;">科研</span>数据，共有456<span style="color: black;">病人</span>参与这个<span style="color: black;">科研</span>。结果<span style="color: black;">显示</span>，GP2和AE37肿瘤疫苗能够改善<span style="color: black;">没</span>病<span style="color: black;">存活</span>期，并且是安全的。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2020年12月9日，SABCS大会<span style="color: black;">颁布</span>了另一项针对HER2<span style="color: black;"><a style="color: black;">阳性乳腺癌GP2肿瘤疫苗</a></span>的Ⅱ期临床<span style="color: black;">科研</span>数据，该疫苗的5年<span style="color: black;">没</span>病<span style="color: black;">存活</span>率为100％，乳腺癌复发率为0％，真是令人赞叹！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">日前</span>该<span style="color: black;">科研</span>正在进行<span style="color: black;"><a style="color: black;">III期</a></span><span style="color: black;">实验</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NO.2 VRP-HER2</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><a style="color: black;">杜克大学</a></span>正在<span style="color: black;">开发</span>一款<span style="color: black;">运用</span>中性病毒载体携带针对HER2蛋白基因信息的疫苗，<span style="color: black;">叫作</span>为<span style="color: black;"><a style="color: black;">VRP-HER2</a></span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">疫苗进入人体后就会瞄准癌细胞中的HER2蛋白，诱发免疫系统对肿瘤细胞发起攻击。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">日前</span>该疫苗正在<span style="color: black;">起步</span>二期临床<span style="color: black;">实验</span>，在晚期HER2+的<span style="color: black;">病人</span>中进行<span style="color: black;">实验</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">治疗与预防两手抓，有了乳腺癌疫苗，相信乳腺癌摘掉“<span style="color: black;">全世界</span><span style="color: black;">第1</span>癌症”的高帽指日可待。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">除了乳腺癌疫苗以外，针对多癌种的疫苗<span style="color: black;">亦</span>正在快速发展<span style="color: black;">周期</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">多癌种疫苗百花齐放</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NO.1 PGV-001</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">PGV-001是一款专门用在标准治疗后的辅助型治疗疫苗，是针对不同<span style="color: black;">病人</span>癌症类型合成的个性化疫苗，<span style="color: black;">拥有</span>治疗多种类型癌症的<span style="color: black;">潜能</span>。可有效清除<span style="color: black;">身体</span>残留的癌细胞，降低复发几率，延长<span style="color: black;">存活</span>时间。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">该疫苗正在进行<span style="color: black;">初期</span>临床<span style="color: black;">实验</span>，在2021年的AACR年会上，该<span style="color: black;">科研</span>公布了1期临床<span style="color: black;">实验</span>数据。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在接受过手术的标准治疗后，13位各类癌症的<span style="color: black;">病人</span>分别接受了7-10剂个性化的PGV-001疫苗和免疫刺激剂poly-ICLC。在其后两年多的随访中，4名<span style="color: black;">病人</span><span style="color: black;">无</span>复发迹象，4名<span style="color: black;">病人</span>正在接受后续治疗，<span style="color: black;">另一</span>3名<span style="color: black;">病人</span>死亡，2名<span style="color: black;">病人</span>失去随访。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">数据<span style="color: black;">显示</span>，该疫苗的中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期高达618天，<span style="color: black;">况且</span>疫苗的耐受性和安全性很好。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NO.2 Riboxxim</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Riboxxim疫苗是将抗原与免疫佐剂Riboxxim<span style="color: black;">一块</span>封装在特殊颗粒中制成的<span style="color: black;"><a style="color: black;">癌症疫苗</a></span>。有可能将肿瘤治愈率从20%<span style="color: black;">加强</span>到75%！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在前期实验中，该疫苗表现出<span style="color: black;">拥有</span>延缓肿瘤生长、防止转移、延长<span style="color: black;">存活</span>周期等让人惊叹的能力。<span style="color: black;">科研</span>人员将疫苗和免疫检查点<span style="color: black;">控制</span>剂联合<span style="color: black;">运用</span>，75%的小鼠肿瘤完全缓解！<span style="color: black;">亦</span>就说该疫苗可能将肿瘤的治愈率<span style="color: black;">加强</span>到75%！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">不仅如此，<span style="color: black;">科研</span>人员还证实了该疫苗<span style="color: black;">能够</span><span style="color: black;">导致</span>乳腺癌、前列腺癌和黑色素瘤的<span style="color: black;">剧烈</span>免疫应答，这<span style="color: black;">寓意</span>着该疫苗适用于多种癌症。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">日前</span>，这款疫苗正在进行I期临床<span style="color: black;">实验</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NO.3、激活T细胞和NK细胞通用型癌症疫苗</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2022年5月25日，美国 Dana-Farber 癌症<span style="color: black;">科研</span>所的<span style="color: black;">科研</span>团队提出了一种癌症疫苗的新设计，这种疫苗靶向两种表面蛋白 MICA 和 MICB，它们<span style="color: black;">能够</span>激活 T 细胞和 NK 细胞的配体，加速免疫系统消灭肿瘤。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">为了验证这种癌症疫苗的有效性和安全性，<span style="color: black;">科研</span>团队在小鼠和<span style="color: black;"><a style="color: black;">恒河猴</a></span>模型中进行了初步测试，结果<span style="color: black;">显示</span>这种疫苗能够增进对普通肿瘤及耐药肿瘤的免疫<span style="color: black;">守护</span>，并且<span style="color: black;">无</span><span style="color: black;">显著</span>的副<span style="color: black;">功效</span>。期待<span style="color: black;">将来</span>该疫苗在临床<span style="color: black;">实验</span>中的表现。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">除此之外，<span style="color: black;">专家</span>们还在疫苗<span style="color: black;">行业</span>进行了<span style="color: black;">非常多</span>探索。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> 牛血液疫苗 </p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2021年2月3日，<span style="color: black;"><a style="color: black;">英国癌症<span style="color: black;">科研</span>基金会</a></span>《英国癌症杂志》<span style="color: black;">发布</span>了一篇关于探讨牛血液细胞提取物制成的疫苗对乳腺癌细胞<span style="color: black;">功效</span>的<span style="color: black;"><a style="color: black;"><span style="color: black;">科研</span>报告</a></span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">科研</span>结果<span style="color: black;">表示</span>，该疫苗<span style="color: black;">不仅</span><span style="color: black;">能够</span>调动免疫系统消灭乳腺癌细胞，还<span style="color: black;">能够</span>使免疫系统<span style="color: black;">很久</span>地记住癌细胞，见一次打一次，从而达到预防乳腺癌复发的目的。<span style="color: black;">咱们</span>期待有<span style="color: black;">更加多</span>的临床<span style="color: black;">实验</span>来验证疫苗的安全性和有效性，<span style="color: black;">早点</span>上市。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> 杂交膜纳米疫苗 </p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">中国科学院国家纳米科技中心的聂广军、吴雁、<span style="color: black;"><a style="color: black;">赵宇亮</a></span>教授成功设计并且<span style="color: black;">开发</span>了一种个性化新型的疫苗，将肿瘤膜抗原与细菌内膜以及大肠杆菌的细胞膜利用纳米技术<span style="color: black;">开发</span>了一种杂交膜纳米疫苗，开启了全新的肿瘤疫苗<span style="color: black;">开发</span>策略，给疫苗<span style="color: black;">开发</span><span style="color: black;">亦</span>带来新的机遇和启发。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> 直接注射在肿瘤部位的疫苗</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">美国斯坦福大学的<span style="color: black;">专家</span>们<span style="color: black;">开发</span>了一种由一小段CpG寡核苷酸的DNA和与OX40受体结合的抗体组合的疫苗。疫苗直接注射到肿瘤部位后，能激活肿瘤内部的T细胞，<span style="color: black;">亦</span><span style="color: black;">便是</span><span style="color: black;">咱们</span>人体的护卫兵，清除注射部位的肿瘤细胞。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">更可喜的是，这些T细胞在完成清理任务后，还<span style="color: black;">能够</span>离开注射位置继续去寻找和破坏<span style="color: black;">身体</span>的其他肿瘤。能够治疗多种不同类型的癌症，<span style="color: black;">乃至</span><span style="color: black;">包含</span>未经治疗的转移瘤。<span style="color: black;">日前</span>，该疫苗正在进行临床<span style="color: black;">科研</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">期待这些疫苗的<span style="color: black;">早点</span><span style="color: black;">开发</span>上市，为<span style="color: black;">更加多</span>的癌症<span style="color: black;">病人</span>带去福音！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">疫苗概览</p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic1.zhimg.com/80/v2-36ea855c9a822e704383246ca51f86c5_720w.webp?source=1def8aca" style="width: 50%; margin-bottom: 20px;"></div>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">虽然这些疫苗都<span style="color: black;">处在</span>临床<span style="color: black;">实验</span><span style="color: black;">周期</span>，但<span style="color: black;">咱们</span>要相信<span style="color: black;">专家</span>们正夜以继日地在抗癌道路上不懈前进，终有一天，肿瘤疫苗能够<span style="color: black;">作为</span>人类的一大利刃，助力<span style="color: black;">解决</span>癌症！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">参考<span style="color: black;">源自</span>：</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;">https://</span><span style="color: black;">.com/news/2021-10-human</span><span style="color: black;">-vaccine-trial-triple-negative.html</span></a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Schneble, EJ; Berry, JS; Trappey, FA; et al.The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax?) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response..Immunotherapy.2014,6(5):519-31</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">CORTES J, CESCON D W, RUGO H S, et al. KEYNOTE-355: Randomized, double-blind, phase Ⅲ study of pembrolizumab ＋ chemotherapy versus placebo ＋ chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J Clin Oncol, 2020, 38(15_ suppl):1000.</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> Brown TA 2nd, Mittendorf EA, Hale DF, Myers JW 3rd, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020 Jun;181(2):391-401. doi: 10.1007/s10549-020-05638-x. Epub 2020 Apr 22. PMID: 32323103.</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;">https://</span><span style="color: black;">investor.greenwichlifesciences.com</span><span style="color: black;">/news-events/press-releases/detail/21/0-recurrence-of-breast-cancer</span></a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> Thomas Urban Marron, et al. An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001). AACR 2021. LB048.</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> The bovine dialysable leukocyte extract IMMUNEPOTENT CRP induces immunogenic cell death in breast cancer cells leading to long-term antitumour memory.Br J Cancer. 2021 Feb 3. Online ahead of print.</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Chen Long,Qin Hao,Zhao Ruifang,Zhao Xiao,Lin Liangru,Chen Yang,Lin Yixuan,Li Yao,Qin Yuting,Li Yiye,Liu Shaoli,Cheng Keman,Chen Hanqing,Shi Jian,Anderson Gregory J,Wu Yan,Zhao Yuliang,Nie Guangjun. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines.. Science translational medicine,2021,13(601):</p>
</span></div>
我完全赞同你的观点，思考很有深度。 大势所趋，用于讽刺一些制作目的就是为了跟风玩梗，博取眼球的作品。 你的见解独到，让我受益匪浅，期待更多交流。
页:
[1]